Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The combination of oxaliplatin, 5-FU, leucovorin, and capecitabine is hypothesized to retain
and potentially improve upon the activity of the FOLFOX regimens. Additionally, the use of an
oral rather than an infusional 5-fu regimen represents a clear advantage in terms of both
patient convenience and lack of associated catheter-related complications.